Richard K Cheng1, Margueritte Cox2, Megan L Neely2, Paul A Heidenreich3, Deepak L Bhatt4, Zubin J Eapen2, Adrian F Hernandez2, Javed Butler5, Clyde W Yancy6, Gregg C Fonarow7. 1. Division of Cardiology, University of Washington Medical Center, Seattle, WA. 2. Duke Clinical Research Institute, Duke University Medical Center, Durham, NC. 3. Division of Cardiology, VA Palo Alto Healthcare System, Stanford University Medical Center, Palo Alto, Ca. 4. Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA. 5. Division of Cardiology, Emory University Medical Center, Atlanta, GA. 6. Division of Cardiology, Northwestern University Medical Center, Chicago, IL. 7. Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, Los Angeles, Ca. Electronic address: gfonarow@mednet.ucla.edu.
Abstract
BACKGROUND: Studies on outcomes among patients with heart failure (HF) with preserved left ventricular ejection fraction (HFpEF), borderline left ventricular ejection fraction (HFbEF), and reduced left ventricular ejection fraction (HFrEF) remain limited. We sought to characterize mortality and readmission in patients with HF in the contemporary era. METHODS: Get With The Guidelines-HF was linked to Medicare data for longitudinal follow-up. Patients were grouped into HFpEF (left ventricular ejection fraction [EF] ≥ 50%), HFbEF (40% ≤ EF < 50%), and HFrEF (EF < 40%). Multivariable models were constructed to examine the relationship between EF and outcomes at 30 days and 1 year and to study trends over time. RESULTS: A total of 40,239 patients from 220 hospitals between 2005 and 2011 were included in the study: 18,897 (47%) had HFpEF, 5,626 (14%) had HFbEF, and 15,716 (39%) had HFrEF. In crude survival analysis, patients with HFrEF had slightly increased mortality compared with HFbEF and HFpEF. After risk adjustment, mortality at 1 year was not significantly different for HFrEF, HFbEF, and HFpEF (HFrEF vs HFpEF, hazard ratio [HR] 1.040 [95% CI 0.998-1.084], and HFbEF vs HFpEF, HR 0.967 [95% CI 0.917-1.020]). Patients with HFpEF had increased risk of all-cause readmission compared with HFrEF. Conversely, risk of cardiovascular and HF readmissions were higher in HFrEF and HFbEF compared with HFpEF. CONCLUSIONS: Among patients hospitalized with HF, patients with HFpEF and HFbEF had slightly lower mortality and higher all-cause readmission risk than patients with HFrEF, although the mortality differences did not persist after risk adjustment. Irrespective of EF, these patients experience substantial mortality and readmission highlighting the need for new therapeutic strategies.
BACKGROUND: Studies on outcomes among patients with heart failure (HF) with preserved left ventricular ejection fraction (HFpEF), borderline left ventricular ejection fraction (HFbEF), and reduced left ventricular ejection fraction (HFrEF) remain limited. We sought to characterize mortality and readmission in patients with HF in the contemporary era. METHODS: Get With The Guidelines-HF was linked to Medicare data for longitudinal follow-up. Patients were grouped into HFpEF (left ventricular ejection fraction [EF] ≥ 50%), HFbEF (40% ≤ EF < 50%), and HFrEF (EF < 40%). Multivariable models were constructed to examine the relationship between EF and outcomes at 30 days and 1 year and to study trends over time. RESULTS: A total of 40,239 patients from 220 hospitals between 2005 and 2011 were included in the study: 18,897 (47%) had HFpEF, 5,626 (14%) had HFbEF, and 15,716 (39%) had HFrEF. In crude survival analysis, patients with HFrEF had slightly increased mortality compared with HFbEF and HFpEF. After risk adjustment, mortality at 1 year was not significantly different for HFrEF, HFbEF, and HFpEF (HFrEF vs HFpEF, hazard ratio [HR] 1.040 [95% CI 0.998-1.084], and HFbEF vs HFpEF, HR 0.967 [95% CI 0.917-1.020]). Patients with HFpEF had increased risk of all-cause readmission compared with HFrEF. Conversely, risk of cardiovascular and HF readmissions were higher in HFrEF and HFbEF compared with HFpEF. CONCLUSIONS: Among patients hospitalized with HF, patients with HFpEF and HFbEF had slightly lower mortality and higher all-cause readmission risk than patients with HFrEF, although the mortality differences did not persist after risk adjustment. Irrespective of EF, these patients experience substantial mortality and readmission highlighting the need for new therapeutic strategies.
Authors: Gordon R Reeves; David J Whellan; Pamela Duncan; Christopher M O'Connor; Amy M Pastva; Joel D Eggebeen; Leigh Ann Hewston; Timothy M Morgan; Shelby D Reed; W Jack Rejeski; Robert J Mentz; Paul B Rosenberg; Dalane W Kitzman Journal: Am Heart J Date: 2016-12-28 Impact factor: 4.749
Authors: H Kirk Hammond; William F Penny; Jay H Traverse; Timothy D Henry; Matthew W Watkins; Clyde W Yancy; Ranya N Sweis; Eric D Adler; Amit N Patel; David R Murray; Robert S Ross; Valmik Bhargava; Alan Maisel; Denise D Barnard; N Chin Lai; Nancy D Dalton; Martin L Lee; Sanjiv M Narayan; Daniel G Blanchard; Mei Hua Gao Journal: JAMA Cardiol Date: 2016-05-01 Impact factor: 14.676
Authors: Melissa C Caughey; Carla A Sueta; Sally C Stearns; Amil M Shah; Wayne D Rosamond; Patricia P Chang Journal: Am J Cardiol Date: 2018-03-28 Impact factor: 2.778
Authors: Brian M Salata; Madeline R Sterling; Ashley N Beecy; Ajayram V Ullal; Erica C Jones; Evelyn M Horn; Parag Goyal Journal: Am J Cardiol Date: 2018-02-07 Impact factor: 2.778
Authors: Lin Li; Bill M Jesdale; Anne Hume; Giovanni Gambassi; Robert J Goldberg; Kate L Lapane Journal: J Cardiol Date: 2017-10-28 Impact factor: 3.159